Novartis del-desiran fails late-stage study in myotonic dystrophy
Novartis said its experimental del-desiran drug for myotonic dystrophy failed in a late-stage study, marking the second pipeline setback in a week.
Swiss drugmaker Novartis BX:NOT said on Tuesday that its experimental drug del-desiran failed in a late-stage study in myotonic dystrophy, a muscle-wasting disease. The result marks a second setback in a week for Novartis as it tries to revive its pipeline.